
Mystery solved: Mysthera Theapeutics launches with $3.5m
Mysthera Therapeutics AG was just founded in Basel, Switzerland by Forty51 Ventures with $3.5m seed capital. Pursuing a first-in-class...

SpliceBio has made up a US $216m alliance with Spark Therapeutics
Under a globally exclusive licence option agreement with Roche AG, SpliceBio secures an upfront payment, opt-in and milestone payments up to $216m...

New detection method for protein degraders
The research team from MPI of Biochemistry and the University of Waterloo have developed a new way to detect those CRLs in the fleet that are...

Cellectis and AstraZeneca in US$2.2bn deal
Under the co-development agreement, that includes a US$80m equity investment and an option for a further equity investment of US$140m by AstraZeneca...

Abingworth raises $356m for new CCD fund
London-headquartered institutional investor Abingworth has closed its new Clinical Co-Development Co-Investment Fund at $356m, exceeding its target...

Crucible Therapeutics spins out with £5m
Crucible Therapeutics Ltd., the newly launched spinout company from the University of Sheffield, secured the investment of £5m from Northern...

Study: New breeding methods hardly contribute to climate protection
Up and down the country, national governments and the EU Commission (EC) are campaigning to facilitate the commercialisation of cis-gentic and...